BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19695277)

  • 1. The effect of dose on 2,3,7,8-TCDD tissue distribution, metabolism and elimination in CYP1A2 (-/-) knockout and C57BL/6N parental strains of mice.
    Hakk H; Diliberto JJ; Birnbaum LS
    Toxicol Appl Pharmacol; 2009 Nov; 241(1):119-26. PubMed ID: 19695277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP1A2 on disposition of 2,3,7, 8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2',4,4',5,5'-hexachlorobiphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice.
    Diliberto JJ; Burgin DE; Birnbaum LS
    Toxicol Appl Pharmacol; 1999 Aug; 159(1):52-64. PubMed ID: 10448125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP1A2 is not required for 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced immunosuppression.
    Smialowicz RJ; Burgin DE; Williams WC; Diliberto JJ; Setzer RW; Birnbaum LS
    Toxicology; 2004 Apr; 197(1):15-22. PubMed ID: 15003330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response relationships of tissue distribution and induction of CYP1A1 and CYP1A2 enzymatic activities following acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice.
    Diliberto JJ; Akubue PI; Luebke RW; Birnbaum LS
    Toxicol Appl Pharmacol; 1995 Feb; 130(2):197-208. PubMed ID: 7871533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.
    Emond C; Birnbaum LS; DeVito MJ
    Environ Health Perspect; 2006 Sep; 114(9):1394-400. PubMed ID: 16966094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated oxidative stress in CYP1A2 knockout (CYP1A2-/-) mice.
    Slezak BP; Diliberto JJ; Birnbaum LS
    Biochem Biophys Res Commun; 1999 Oct; 264(2):376-9. PubMed ID: 10529372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CYP1A2 in hepatic sequestration of dioxin: studies using CYP1A2 knock-out mice.
    Diliberto JJ; Burgin D; Birnbaum LS
    Biochem Biophys Res Commun; 1997 Jul; 236(2):431-3. PubMed ID: 9240455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat.
    Evans MV; Andersen ME
    Toxicol Sci; 2000 Mar; 54(1):71-80. PubMed ID: 10746933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subchronic Exposure of [3H]- 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female B6C3F1 mice: relationship of steady-state levels to disposition and metabolism.
    Diliberto JJ; DeVito MJ; Ross DG; Birnbaum LS
    Toxicol Sci; 2001 Jun; 61(2):241-55. PubMed ID: 11353133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2.
    Kedderis LB; Diliberto JJ; Linko P; Goldstein JA; Birnbaum LS
    Toxicol Appl Pharmacol; 1991 Oct; 111(1):163-72. PubMed ID: 1949032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver.
    Sato S; Shirakawa H; Tomita S; Ohsaki Y; Haketa K; Tooi O; Santo N; Tohkin M; Furukawa Y; Gonzalez FJ; Komai M
    Toxicol Appl Pharmacol; 2008 May; 229(1):10-9. PubMed ID: 18295293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Smith AG; Clothier B; Carthew P; Childs NL; Sinclair PR; Nebert DW; Dalton TP
    Toxicol Appl Pharmacol; 2001 Jun; 173(2):89-98. PubMed ID: 11384210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice.
    Derkenne S; Curran CP; Shertzer HG; Dalton TP; Dragin N; Nebert DW
    Pharmacogenet Genomics; 2005 Jul; 15(7):503-11. PubMed ID: 15970798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Walker NJ; Portier CJ; Lax SF; Crofts FG; Li Y; Lucier GW; Sutter TR
    Toxicol Appl Pharmacol; 1999 Feb; 154(3):279-86. PubMed ID: 9931287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time- and concentration-dependent induction of CYP1A1 and CYP1A2 in precision-cut rat liver slices incubated in dynamic organ culture in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Drahushuk AT; McGarrigle BP; Slezak BP; Stegeman JJ; Olson JR
    Toxicol Appl Pharmacol; 1999 Mar; 155(2):127-38. PubMed ID: 10053167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacodynamically responsive model of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) transfer between liver and fat at low and high doses.
    Roth WL; Ernst S; Weber LW; Kerecsen L; Rozman KK
    Toxicol Appl Pharmacol; 1994 Jul; 127(1):151-62. PubMed ID: 8048047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and time-dependent effects.
    Santostefano MJ; Wang X; Richardson VM; Ross DG; DeVito MJ; Birnbaum LS
    Toxicol Appl Pharmacol; 1998 Aug; 151(2):294-310. PubMed ID: 9707506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver.
    Tritscher AM; Goldstein JA; Portier CJ; McCoy Z; Clark GC; Lucier GW
    Cancer Res; 1992 Jun; 52(12):3436-42. PubMed ID: 1596902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) distribution and cytochrome P4501A induction in young adult and senescent male mice.
    Pegram RA; Diliberto JJ; Moore TC; Gao P; Birnbaum LS
    Toxicol Lett; 1995 Mar; 76(2):119-26. PubMed ID: 7725343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.